Mag3 Radiopharmacy (Betiatide)

• Betiatide is used in diagnostic imaging of the renal system.
• Renal imaging: enables visualization of kidney perfusion and excretion to assess function and drainage.
• Renal transplant evaluation: assists in monitoring graft perfusion and function post‑transplant.
• Urography: supports assessment of urinary tract obstruction.

• Betiatide acts as a radiotracer that is rapidly cleared by tubular secretion in the kidneys. After intravenous injection, it distributes in the renal cortex, allowing gamma camera detection of renal blood flow, filtration, and excretory pathways, thereby providing functional imaging of renal physiology.

Adverse reactions may occur following administration of Betiatide.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Vomiting: occasional emesis after injection.
• Headache: transient mild headache.
• Transient flushing: brief skin redness.
• Metallic taste: brief sensation in mouth.
• Mild hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, or swelling.
• Anaphylaxis: severe, potentially life‑threatening hypersensitivity.
• Severe hypotension: marked blood pressure fall requiring intervention.
• Radiation‑induced skin injury: localized skin changes at injection site.
• Renal toxicity: worsening of kidney function.
• Severe arrhythmia: abnormal heart rhythm requiring monitoring.

• When using Betiatide, clinicians should observe several safety measures.
• Assess renal function: evaluate baseline kidney function before administration.
• Pregnancy: avoid use unless the benefit clearly outweighs potential fetal risk.
• Breastfeeding: discontinue if possible, as the drug may be excreted in milk.
• Concurrent radiopharmaceuticals: avoid co‑administration to prevent imaging interference.
• Allergy history: screen for hypersensitivity to any component of the formulation.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Betiatide may interact with other medicines and agents.

Major Interactions (Avoid)

• Nephrotoxic drugs: may exacerbate renal toxicity.
• Competing radiopharmaceuticals: can interfere with imaging results.
• Contrast agents: may alter renal clearance of Betiatide.
• High‑dose diuretics: affect excretion pattern and image quality.
• Radiation therapy: additive radiation exposure risk.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may modify renal handling of the tracer.
• NSAIDs: can affect renal perfusion and tracer distribution.
• Beta‑blockers: may influence hemodynamics during imaging.
• Antihistamines: could mask early signs of allergic reaction.
• Electrolyte disturbances: monitor serum potassium and sodium levels.